Certara, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has announced that it has released D360 version 9.0 along with D360 Express, its data informatics platform for discovery scientists. D360 is a self-service data access, integration and visualization solution used to query multiple cheminformatics and bioinformatics data sources and make informed go/no-go and next step research decisions. It is used by more than 5,000 scientists worldwide at both large pharma and specialty research organizations.

“Scientists choose D360 because it allows them to accelerate their ‘time to insight.’ It enables them to access current data faster, spend more time on analysis, and ask and answer questions ‘on the fly,” said Certara Senior director, product management David Lowis, D. Phil. “To that end, version 9 offers ‘virtual compound support,’ an exciting new capability that allows users to create new chemical structure ideas that can be assessed, shared and prioritized alongside existing project compounds extending D360’s capabilities from pure analysis into the world of design. D360’s upgraded data query and handling capabilities also allow users to investigate more complex assays and study results, an expertise that will increasingly be needed as the industry moves further into precision medicine.”

Certara’s D360 is the industry-leading scientific informatics platform for integrating and leveraging the large amounts of diverse scientific data generated in discovery research. D360 enables scientists to cut dramatically the time required to provision data. They estimate that this change allows them to increase by more than 50 per cent the time they spend performing pivotal scientific modeling and analysis, advancing compounds, and making informed decisions.

Certara is a leading decision support technology and consulting organization committed to optimizing drug development and improving health outcomes. Certara’s solutions, which span drug discovery through patient care, use the most scientifically-advanced modeling and simulation technologies and regulatory strategies to increase the probability of regulatory and commercial success. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions, and key regulatory agencies.